CSChie Seki

Chie Seki

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Chie Seki has a total of 195 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • In Vivo Topographic Associations Between Tau Pathology, Atrophy, and Symptom Domains in Patients With Progressive Supranuclear Palsy

    byĀ Yuko Kataoka, Ryoji Goto, Yoshikazu Chishiki, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Sho Moriguchi, Yuki Momota, Tetsuji Kamada, et al.

  • Open Access

    A high-resolution TOF-DOI PET system for nonhuman primate neuroimaging

    byĀ Taiyo Ishikawa, Go Akamatsu, Shigeki Ito, Hiroshi Mizuma, Chie Seki, Yuji Nagai, Takashi Okauchi, Hidekatsu Wakizaka, Yuma Iwao, Hideaki Tashima, et al.

    Background: Unlike clinical PET, time-of-flight (TOF) measurement offers limited benefits in nonhuman primate (NHP) imaging due to the smaller object size, whereas depth-of-interaction (DOI) is essential for small-diameter scanners. We developed a novel high-resolution NHP brain PET system with TOF and DOI capabilities, demonstrating that both TOF and DOI information improved the quality of NHP brain PET—crucial for preclinical neuroscience research—for the first time to our knowledge. Methods: Our original crosshair light-sharing (CLS) detector with a 14 Ɨ 14 array of 1.6 mm-pitch and 15 mm-length fast-LGSO crystals was used. The scanner had 170-mm ring diameter and 156-mm axial field of view. The performance characteristics were evaluated according to the NEMA NU4 and NU2 standards. The visibility of a 22 Na multi-rod phantom was also evaluated. 18 F-FDG brain PET of a macaque monkey was performed. Results: Radial, tangential, and axial resolutions at 5 mm offset were 1.5, 1.3, and 1.2 mm. The radial resolution at 50 mm offset was improved from 4.1 to 2.1 mm by using DOI information. The 0.75 mm rods were partially distinguished with an iterative reconstruction. The peak sensitivity was 1.5% with an energy window of 440–620 keV. The peak noise-equivalent count rate for the monkey-sized scatter phantom was 65.1 kcps at 102.8 MBq. The TOF resolution was 242 ps. Both TOF and DOI information quantitatively improved gray matter visibility. Conclusions: This study clarified that the synergy of TOF and DOI information offers benefits even for NHP brain PET.

  • Open Access

    Remote network for cognitive symptoms derived from tau accumulation in progressive supranuclear palsy

    byĀ Yuki Hori, Hironobu Endo, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Shin Kurose, Yuki Momota, Naomi Kokubo, Chie Seki, Sho Moriguchi, et al.

    Progressive supranuclear palsy (PSP) is a neurodegenerative disorder with motor and cognitive impairments. Whereas motor symptoms are associated with subcortical tau deposits, the mechanisms underlying the cognitive symptoms remain unclear due to heterogeneous and primarily subcortical distribution of pathological tau deposits. Here, we combined tau-PET (tau positron emission tomography) using a high-contrast probe we developed with a normative connectome in 37 patients with PSP and 48 healthy controls. We found that tau deposition sites functionally connected to a common cortical network that could not be derived from atrophy. This network predominantly overlapped with canonical action-mode and frontoparietal networks, which support adaptive, goal-directed behavior. Whereas the extent of primary tau deposition predicted motor symptoms, the normative connectivity strength from tau deposition sites to the identified cortical network explained the severity of cognitive deficits. These findings suggest a previously unknown mechanism that cognitive, but not motor, deficits in PSP arise from remote effects of tau deposition—independent of atrophy—via convergent connectivity to a common cortical network.


  • Open Access

    Spatiotemporal Tau Accumulation and Its Clinical Impact on PSP: Longitudinal Florzolotau (18F) PET

    byĀ Yoshikazu Chishiki, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Kenta Osawa, Asaka Oyama, Hideki Matsumoto, Masanori Ichihashi, Yuki Momota, Tetsuji Kamada, et al.

    Background: Florzolotau (18F) positron emission tomography (florzolotau PET) enables high-contrast in vivo detection of four-repeat tau pathology in progressive supranuclear palsy (PSP), but whether longitudinal tau imaging reflects disease progression remains unclear. Objectives: To explore longitudinal tau accumulation using florzolotau PET and evaluate its association with clinical progression in PSP. Methods: A total of 26 patients with PSP (18 Richardson’s syndrome [PSP-RS], 8 non-RS) and 10 age- and sex-matched healthy controls (HCs) underwent florzolotau PET, MRI, and clinical assessments at baseline and after 1 year. Regional standardized uptake value ratios (SUVR) were extracted across 57 regions of interest. Partial least squares (PLS) multivariate analyses revealed regions with elevated baseline SUVR and longitudinal increase (Ī”SUVR) in PSP relative to HCs, alongside regions where Ī”SUVR was associated with changes in PSP Rating Scale scores. Results: At baseline, tau deposition was most prominent in the globus pallidus (GP) and midbrain in patients with PSP. Longitudinal tau increases were observed in the GP, frontoparietal cortex, and cerebellum, whereas minimal progression was observed in the midbrain. GP tau accumulation exhibited the strongest association with clinical progression in the PLS model among PSP-RS and a univariate correlation (Spearman’s ρ = 0.674, p = 0.002). Conclusions: This study provides in vivo evidence of the spatiotemporal progression of tau pathology in PSP. In the GP, tau accumulation emerges early and continues to rise with clinical deterioration. These findings support the utility of florzolotau PET for monitoring disease progression and as a biological outcome measure in tau-targeted therapeutic trials.

  • Open Access

    Remote Cortical Network for Frontal Cognitive Symptoms Derived from Tau Accumulation in Progressive Supranuclear Palsy

    byĀ Yuki Hori, Hironobu Endo, Kenji Tagai, Yuko Kataoka, Ryoji Goto, Shin Kurose, Yuki Momota, Naomi Kokubo, Chie Seki, Sho Moriguchi, et al.

    Progressive Supranuclear Palsy (PSP) is a neurodegenerative disorder characterized by impaired movement and frontal cognitive dysfunctions. While motor symptoms have been linked with subcortical tau deposits, network mechanisms underlying the frontal cognitive symptoms remain unclear because pathological tau accumulation is quite limited within the frontal cortex and heterogeneously distributed primarily in the subcortical regions. Here, we combined tau-PET using a high-contrast probe we have recently developed with normative connectome to resolve this issue. Tau-deposition sites were connected to a common cortical network that could not be identified through similar analyses based on atrophy detected by structural MRI. This network was predominantly overlapped with canonical action-mode and frontoparietal networks, which jointly support adaptive and goal-directed behavior. Critically, while the degree of subcortical primary tau deposition correlated with motor symptoms, only the degree of connectivity from tau-deposition sites to the derived cortical network explained the frontal cognitive deficits of individual patients. These findings suggest a novel mechanism that frontal cognitive impairments, but not motor deficits, in PSP are derived from remote effects of tau deposits, independent of atrophy, through the convergent connectivity to the identified common cortical network.


  • Open Access

    Development of a novel radioiodinated compound for amyloid and tau deposition imaging in Alzheimer's disease and tauopathy mouse models

    byĀ Xiyan Rui, Xinran Zhao, Nailian Zhang, Yuzhou Ding, Chie Seki, Maiko Ono, Makoto Higuchi, Ming-Rong Zhang, Yong Chu, Ruonan Wei, et al.


  • Washout in in-beam PET as a biomarker of tumor vascular condition: a feasibility study in rats

    byĀ C. Toramatsu, A. Mohammadi, H. Wakizaka, H. Sudo, N. Nitta, C. Seki, Y. Ikoma, I. Kanno, T. Yamaya

    Positron emission tomography (PET) has been used for treatment verification in charged particle therapy. For accurate dose verification, modeling and correction of the biological washout effect of the positron emitters, which is influenced by the tumor vasculature condition, has been an issue. Conversely, the biological washout effect indicates changes of the tumor vasculature condition, which is known to influence radiation response. At present, blood circulatory changes in a tumor are measured using dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI) to evaluate tumor radiation response. Here, measuring the biological washout rate of the produced positron emitters may also function to evaluate tumor radiation response, in a similar manner to DCE-MRI. Therefore, this study compared the washout rates between in-beam PET during 12 C ion beam irradiation and DCE-MRI. Different vascular types of the tumor model were prepared using six nude rats. The tumor of each nude rat was irradiated by a 12 C ion beam and scanned by in-beam PET on the first day. On the second day, the DCE-MRI experiment was performed for the same six nude rats. The washout rate of the produced positron emitters (k 2,1st ) and the MRI contrast agent (k 2a ) were derived using the single tissue compartment model. A linear correlation was observed between k 2,1st and k 2a , and they were inversely related to fractional necrotic volume. This is the first study which showed the feasibility of washout in in-beam PET as a biomarker for the tumor vascular condition; a clear correlation was seen between the washout rate of the positron emitters in tumor tissue produced via a nuclear fragmentation reaction and the washout of the MRI contrast agent administrated intravenously.

  • Open Access

    Development and Performance Assessment of a Novel Plasma p-Tau181 Assay Reflecting Tau Tangle Pathology in Alzheimer’s Disease

    byĀ Kenji Tagai, Harutsugu Tatebe, Sayo Matsuura, Zhang Hong, Naomi Kokubo, Kiwamu Matsuoka, Hironobu Endo, Asaka Oyama, Kosei Hirata, Hitoshi Shinotoh, et al.

    Several blood-based assays for phosphorylated tau (p-tau) have been developed to detect brain tau pathologies in Alzheimer’s disease (AD). However, plasma p-tau measured by currently available assays is influenced by brain amyloid and, therefore, could not accurately reflect brain tau deposits. Here, we devised a novel immunoassay that can quantify N- and C-terminally truncated p-tau fragments (mid-p-tau181) in human plasma. We measured plasma p-tau181 levels in 164 participants who underwent both amyloid and tau positron emission tomography (PET) scans using mid-p-tau181 and conventional p-tau181 assays. The mid-p-tau181 assay displayed stronger correlations with tau PET accumulation than the conventional assay in the AD continuum and accurately distinguished between tau PET-positive and -negative cases. Furthermore, the mid-p-tau181 assay demonstrated a trajectory similar to tau PET alongside cognitive decline. Consequently, our mid-p-tau181 assay could be useful in evaluating the extent of brain tau burden in AD.

  • Open Access

    Investigating Neural Dysfunction with Abnormal Protein Deposition in Alzheimer’s Disease Through Magnetic Resonance Spectroscopic Imaging, Plasma Biomarkers, and Positron Emission Tomography

    byĀ Kiwamu Matsuoka, Kosei Hirata, Naomi Kokubo, Takamasa Maeda, Kenji Tagai, Hironobu Endo, Keisuke Takahata, Hitoshi Shinotoh, Maiko Ono, Chie Seki, et al.

    In Alzheimer’s disease (AD), aggregated abnormal proteins induce neuronal dysfunction. Despite the evidence supporting the association between tau proteins and brain atrophy, further studies are needed to explore their link to neuronal dysfunction in the human brain. To clarify the relationship between neuronal dysfunction and abnormal proteins in AD-affected brains, we conducted magnetic resonance spectroscopic imaging (MRSI) and assessed the neurofilament light chain plasma levels (NfL). We evaluated tau and amyloid-β depositions using standardized uptake value ratios (SUVRs) of florzolotau (18F) for tau and 11 C-PiB for amyloid-β positron emission tomography in the same patients. Heatmaps were generated to visualize Z scores of glutamate to creatine (Glu/Cr) and N-acetylaspartate to creatine (NAA/Cr) ratios using data from healthy controls. In AD brains, Z score maps revealed reduced Glu/Cr and NAA/Cr ratios in the gray matter, particularly in the right dorsolateral prefrontal cortex (rDLPFC) and posterior cingulate cortex (PCC). Glu/Cr ratios were negatively correlated with florzolotau (18F) SUVRs in the PCC, and plasma NfL levels were elevated and negatively correlated with Glu/Cr (P = 0.040, r = āˆ’0.50) and NAA/Cr ratios (P = 0.003, r = āˆ’0.68) in the rDLPFC. This suggests that the abnormal tau proteins in AD-affected brains play a role in diminishing glutamate levels. Furthermore, neuronal dysfunction markers including Glu/tCr and NAA/tCr could potentially indicate favorable clinical outcomes. Using MRSI provided spatial information about neural dysfunction in AD, enabling the identification of vulnerabilities in the rDLPFC and PCC within the AD’s pathological context.

  • A quantitative in vivo imaging platform for tracking pathological tau depositions and resultant neuronal death in a mouse model

    byĀ Taeko Kimura, Maiko Ono, Chie Seki, Kazuaki Sampei, Masafumi Shimojo, Kazunori Kawamura, Ming-Rong Zhang, Naruhiko Sahara, Yuhei Takado, Makoto Higuchi

    Purpose Depositions of tau fibrils are implicated in diverse neurodegenerative disorders, including Alzheimer’s disease, and precise assessments of tau pathologies and their impacts on neuronal survival are crucial for pursuing the neurodegenerative tau pathogenesis with and without potential therapies. We aimed to establish an in vivo imaging system to quantify tau accumulations with positron emission tomography (PET) and brain atrophy with volumetric MRI in rTg4510 transgenic mice modeling neurodegenerative tauopathies. Methods A total of 91 rTg4510 and non-transgenic control mice underwent PET with a tau radiotracer, 18F-PM-PBB3, and MRI at various ages (1.8–12.3 months). Using the cerebellum as reference, the radiotracer binding in target regions was estimated as standardized uptake value ratio (SUVR) and distribution volume ratio (DVR). Histopathological staining of brain sections derived from scanned animals was also conducted to investigate the imaging-neuropathology correlations. Results 18F-PM-PBB3 SUVR at 40–60 min in the neocortex, hippocampus, and striatum of rTg4510 mice agreed with DVR, became significantly different from control values around 4–5 months of age, and progressively and negatively correlated with age and local volumes, respectively. Neocortical SUVR also correlated with the abundance of tau inclusions labeled with PM-PBB3 fluorescence, Gallyas-Braak silver impregnation, and anti-phospho-tau antibodies in postmortem assays. The in vivo and ex vivo 18F-PM-PBB3 binding was blocked by non-radioactive PM-PBB3. 18F-PM-PBB3 yielded a 1.6-fold greater dynamic range for tau imaging than its ancestor, 11C-PBB3. Conclusion Our imaging platform has enabled the quantification of tau depositions and consequent neuronal loss and is potentially applicable to the evaluation of candidate anti-tau and neuroprotective drugs.